Selera Medical Treats Heart Failure Like a Plumbing Problem

The cruelest thing about heart failure is not the heart. It is the water. Fluid backs up in the lungs and the legs, patients cannot breathe, they go to the hospital, a nurse pulls the fluid out over three or four days, and they go home - onto the same medications that let it happen in the first place. A few weeks or months later, it happens again. Selera Medical, a Y Combinator-backed startup from the Winter 2024 batch, was built around a single stubborn question: what if you fixed the plumbing once, instead of chasing the water forever?

Founded in 2023 by chief executive Stacie Arechavala and chief technology officer Kevin Bui, Selera is developing a device-based treatment for the fluid overload that drives most of the suffering in chronic heart failure. The company's approach has a name that sounds like a friendly robot and works like a bypass: MILO, or minimally invasive lymphatic offloading. The pitch is direct. Instead of a lifelong drug regimen that loses potency over time, Selera wants to perform one procedure that reopens the body's own drainage network and keeps the fluid moving.

01 / The ProblemA revolving door nobody had unhinged

Heart failure does not mean the heart has stopped. It means the heart can no longer pump strongly enough to keep fluid circulating the way it should. That fluid leaks out of the bloodstream and pools in tissue - the interstitial space - where it causes breathlessness, swelling, fatigue, and the sensation, as patients describe it, of slowly drowning on dry land. When it gets bad enough, they are admitted, drained, and discharged. The cycle is so predictable that hospitals have a word for the readmissions: the revolving door.

What makes it grim is the math. After a hospitalization for heart failure, roughly half of patients are no longer alive two years later - a survival curve often compared, uncomfortably, to stage 4 cancer. And the standard treatments, diuretics chief among them, are older than the moon landing. They help, until they do not. Over time the body adapts, the doses climb, and the drugs stop clearing fluid the way they once did.

02 / The IdeaBorrowing the body's second drainage system

The insight behind Selera is almost embarrassingly simple, which is usually the sign of a good one. The body already has a system whose entire job is to move fluid the heart cannot: the lymphatic system, a network of vessels that collects excess fluid from tissue and returns it to circulation. In heart failure, that system gets overwhelmed. Selera's MILO procedure is designed to give it help - opening new lanes for trapped interstitial fluid to flow freely, offloading the backlog, and easing the pressure that drives symptoms.

Crucially, it is meant to be done once. Where a drug asks the patient to manage a condition daily and forever, Selera is aiming for a minimally invasive intervention that addresses the mechanism directly and then gets out of the way. That is the difference between managing a leak with buckets and re-routing the pipe.

03 / The FoundersTwo engineers who watched surgeries first

Both founders came out of Stanford Biodesign, a fellowship famous for a particular discipline: before anyone touches a whiteboard, they spend months in clinics and operating rooms watching what actually goes wrong. It is a program built to make engineers fall in love with a problem rather than a solution.

Stacie Arechavala, the CEO, holds a background in biomedical engineering and engineering management from Duke and spent time as an R&D engineer developing cardiovascular devices at Medtronic before her Biodesign fellowship - the rare founder who has built regulated medical hardware inside a large company and run operations at a startup. Kevin Bui, the CTO, did his undergraduate work at Stanford and earned a PhD in bioengineering from the University of Pennsylvania. Between them: the deep-tech chops to invent a device, and the operational sense to move it toward patients.

04 / The DifferenceA device where everyone else brought a drug

Heart failure is a crowded field, but most of the crowd is standing somewhere else. Neuromodulation companies like CVRx and Impulse Dynamics stimulate nerves or heart muscle. Others, like Adona Medical and FineHeart, work on implants and pumps that manage pressure and flow. And behind all of them sits the incumbent that everyone actually competes with: the prescription pad, with its decades-old diuretics.

Selera's differentiation is not that its device is fancier. It is that the target is different. By going after the fluid itself - through the lymphatic route, in a single procedure - Selera is planting a flag on a mechanism the rest of the field has largely left alone.

Approach	What it targets	One-time?
Diuretics (standard care)	Fluid, via the kidneys	No - daily, lifelong
Neuromodulation devices	Nerve / cardiac signaling	Implant-based
Pumps & pressure implants	Blood flow & pressure	Implant-based
Selera Medical (MILO)	Interstitial fluid, via the lymphatic system	Yes - one procedure

05 / The BusinessThe long medtech road ahead

Selera is early. The $500,000 pre-seed it raised in April 2024, alongside its Y Combinator backing, is seed capital for a company that will ultimately need to clear the tall regulatory bar every implantable or interventional device faces. Its website, at the time of writing, is still a placeholder. This is a pre-revenue, pre-market company with a hard science problem and a two-person core team.

The eventual business model is the standard medtech one: prove safety and efficacy in trials, secure regulatory clearance, and sell a device and procedure used by interventional cardiologists and heart failure specialists inside hospital systems, reimbursed through insurers. The addressable population - those 6.5 million-plus Americans with heart failure, and many more worldwide - is enormous. So is the distance between a compelling thesis and an approved product. Selera has picked the kind of problem where being right could matter for a very long time, and where being early means years of careful work.

06 / The StakesWhy this matters in ten years

If Selera is wrong, it joins a long list of medical device startups with elegant ideas and difficult biology. If it is right, it does something the field has wanted for sixty years: it changes the trajectory of a disease, rather than the comfort of a bad afternoon. That is the bet two former Biodesign fellows are making - that heart failure's revolving door has a hinge, and that the hinge is fluid.